ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...
SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...
Market Growth Driven by Rising Demand for Point-of-Care Diagnostics, Increasing Prevalence of Chronic and Infectious Diseases, Emergency Department Needs, and Technological Innovations
REDDING, Calif., June...
TORONTO, June 26, 2025 /PRNewswire/ -- MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a...
Study is the first to explore the impact of genetic ancestry on tumor genomics in T-ALL
PHILADELPHIA and MEMPHIS, Tenn., June 24, 2025 /PRNewswire/ --...
PITTSBURGH, June 21, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence...